Results 41 to 50 of about 108,823 (265)

Pharmacology of proton pump inhibitors [PDF]

Current Gastroenterology Reports, 2008
The gastric H,K-ATPase is the primary target for the treatment of acid-related diseases. Proton pump inhibitors (PPIs) are weak bases composed of two moieties, a substituted pyridine with a primary pK(a) of about 4.0, which allows selective accumulation in the secretory canaliculus of the parietal cell, and a benzimidazole with a second pK(a) of about ...
Jai Moo, Shin, George, Sachs
openaire   +2 more sources

Molecular characterization of covRS mutations in M1UK Streptococcus pyogenes

FEBS Open Bio, EarlyView.
Group A Streptococcus (GAS) acquires covRS mutations driving a hypervirulent bacterial state, frequently associated with invasive disease‐like necrotizing fasciitis. We demonstrate that the newly emerged M1UK GAS lineage can also acquire these mutations.
Jarrad Pritchard, Emma‐Jayne Proctor, Jiawa Wang, Nikolas P. Johnston, Andrew Hayes, Georgia McCorkell, Haibo Yu, Jai Tree, Mark R. Davies, Mark J. Walker, Ronald Sluyter, Stephan Brouwer, Martina L. Sanderson‐Smith   +12 more
wiley   +1 more source

Antiplatelet agents and proton pump inhibitors – personalizing treatment

Pharmacogenomics and Personalized Medicine, 2010
Eugene Lin, Rajiv Padmanabhan, Majaz MoonisDepartment of Neurology, University of Massachusetts Medical School and UMass Memorial Medical Center, Worcester, Massachusetts, USAIntroduction: Antiplatelet therapy remains one of the cornerstones in the ...
Eugene Lin, Rajiv Padmanabhan, Majaz Moonis   +2 more
doaj  

Clopidogrel and proton pump inhibitors [PDF]

Canadian Medical Association Journal, 2014
In their comprehensive review of antithrombotic agents following acute coronary syndromes, Matteau and Bhatt[1][1] discuss the drug interaction between proton pump inhibitors and clopidogrel. They note that the COGENT trial, led by Bhatt, found no increased risk of major cardiovascular events at ...
openaire   +2 more sources

From energy provision to protein synthesis: Tunnelling nanotubes as mediators of intercellular metabolic cooperation in cancer

FEBS Open Bio, EarlyView.
The cytoskeleton‐mediated transport of mitochondria via tunnelling nanotubes restores respiration, increases ATP production, rescues cells from apoptosis, activates the AKT/mTOR signalling pathway, promotes cell migration and invasiveness, contributes to cancer progression and treatment resistance.
Stanislava Martínková, Jan Trnka
wiley   +1 more source

Refractory gastroesophageal reflux disease

Arquivos de Gastroenterologia, 2012
CONTEXT: Gastroesophageal reflux disease (GERD) is a condition which develops when the reflux of stomach contents causes troublesome symptoms and/or complications.
Joaquim Prado P. Moraes-Filho
doaj   +1 more source

Anaphylaxis to proton pump inhibitors

Allergologia et Immunopathologia, 2002
Proton pump inhibitors (PPI) are widely used for the treatment of peptic ulcer, but cases of anaphylactic reactions have rarely been described. We present a patient who experienced an episode of urticaria 30 minutes after oral intake of an omeprazole capsule. Skin prick tests to omeprazole, pantoprazole and lansoprazole were positive.
P, González, V, Soriano, P, López, E, Niveiro   +3 more
openaire   +2 more sources

Characteristics and Outcomes of Male Participants in a Multicenter Longitudinal Australian Study Cohort

Arthritis Care &Research, EarlyView.
Objective The aim of this study was to determine the differences in demographic, serologic, and clinical characteristics between male and female patients with systemic sclerosis (SSc) in an Australian cohort. Methods This was a retrospective observational study using data from the Australian Scleroderma Cohort Study.
Emily Lin, Dylan Hansen, Laura Ross, Gene‐Siew Ngian, Susanna Proudman, Gabor Major, Maryam Tabesh, Mandana Nikpour, Jennifer Walker, Lauren Host, Nava Ferdowsi, Alannah Quinlivan, Wendy Stevens, Joanne Sahhar, Diane Apostolopoulos   +14 more
wiley   +1 more source

When proton pump inhibitors are compared, are there specific cases in which a certain proton pump inhibitors should be particularly preferred?

The Turkish Journal of Gastroenterology, 2017
Currently, proton pump inhibitors (PPIs) are widely used either over the counter or on prescription drugs. PPI’s are frequently used with other drugs when elderly and chronic desease burden population is taken to consideration.
Altay Çelebi, Hasan Yılmaz
doaj   +1 more source

Population-based cohort study: proton pump inhibitor use during pregnancy in Sweden and the risk of maternal and neonatal adverse events

BMC Medicine, 2022
Background Approximately half of all women suffer from heartburn at some stage during pregnancy. The most effective treatment is proton pump inhibitors, but the safety of use during pregnancy cannot be guaranteed. This study aimed to elucidate the effect
Esmee M. Breddels, Johanna Simin, Romina Fornes, Helene Lilja Engstrand, Lars Engstrand, Robin Bruyndonckx, Nele Brusselaers   +6 more
doaj   +1 more source